The JV will develop OTC products line, which includes skin creams, nutraceutical and cosmetic products for the international markets.
Cannabis Science president and CEO Robert Melamede said Cannabis has an opportunity to embrace, support, and develop new and existing product lines already sold by Dupetit Natural Products.
"The potential of this new revenue stream as well as others, moves us closer to achieving our revenue goal of $9 million in earnings in 3 years so that we can realize our goal of one cent per share in earnings for the shareholders," Melamede added.
Cannabis Science Investor Relations vice president Robert Kane said Europe is an important market for Cannabis Science.
"What we hear from our investors is that they are excited that we are a global company because of the growth opportunities outside the US market,” Kane added.